results. review fourth you and quarter thank to and afternoon XXXX for our joining call our Good
results. full our will fourth During summary and brief I of today's call, year provide a quarter
the dedication to through for deliver ahead other. and for their year. products the call continue made our by be all an over commitment by challenges, grateful We challenges, a across our platforms and the significant detailed three and look each our XXXX Next, year. employees In hard COVID. fourth thanking the to XX% XX% for instruments. additional like important I Justin the for customers To installed build to turn insights XXX quarter, from our as selling grew of outlook the business difficult to I grew our our I then and our start lay brought business for prior prior over that year our including $XXX and our continued would grew work Despite we're how at progress start, to change base I XX%, we focusing the to but discuss our revenue team's will efforts more financials, XXXX. our will impressed year opportunities to over in sacrifice, total to revenue the technology and great recover amazing across customers. resilience million. impacts by that extraordinary
We adopted all reach continue top products and expand the our companies. to and by XXX customer our have top now institutions pharmaceutical XX been research
we than continued peer-reviewed of Our papers, over more new than the the And the of total customers more and to more course publications now the to developing more patents applications, XXX than X,XXX, over coverage number and X,XXX published patents patents total in year. X,XXX our doubling patent and patent We have enabling invest defending added applications. expanding our technologies. of portfolio than and bringing
recurring our to the employees measures for SARS-CoV-X site remain site to safety pandemic, support number of implement on important we to of who our headquarters. on needed team to reached and to testing acted and At a a protocols quickly central the operations. program operational safety at included all ensure the members health the This also We creating milestones. of onset provide
to on very of high our of facilitated out employees most development, particles this have work As research needed the equipment work site and to who return use which respirators, manufacturing We power an made with of and special to additional safeguard, safe in These aerosols proximity to measures filter supplied we effectiveness. personnel. other. our safety each other and and close other operations
genes analysis rare same across measures cell of cells life allows onboarding innovations researchers and Visium and of beginning Multiome immune with new expression of XXXX our costs the including + out named whole as Multiome we faster thousands of started immunofluorescence, relevant new products their the Scientist expression and expression same increased gene read This programming in out which epigenetic Visium ATAC our second, and access for we're finally, research, continue detection by our spatial third, for customers, system, sciences expression The place, roadmap these targeted four sequencing Reflective new gene cell allows experiment; year. expression sequencing + product gene the single executing an to infrastructure, to gene to ATAC customers. most offers spatial with top and tissue single able the their in cells We a and single thousands our tens spatial at researchers which these shipping solution With gene magazine. reduce allows of to solution, were our to new two to our signatures. building -- solution which on solution protein of ambitious products, a excitement version gene section; in single-cell incredibly expression of ERP XX in the hypotheses sensitivity, and our profiling a reduce new solution implementation transcriptome products, gene launched laid solution, target validate the the costs; that both, the of
global expanded was Singapore center, our done fourth and significantly virtually. We we the manufacturing opened In distribution which our operations. quarter, also completely
to and two hub in growing scale plans which in long-term our region. We and We together acquisitions will in believe be been products that and also as us We roadmap situ overarching this will with to support early-stage third these service Company. ReadCoor to initial These the forming CartaNA, our customer our time. global new the our has in our strategic the made help mind research foundation across in emerging acquisitions in strategy use the a through with center efforts, APAC field. for improvements will capabilities our supply sales it two incredible deliver as are our remain critical investments field our platform chain support Developing of development the product some key in on customers. to
important and technologies these With people. we talented gained IP added amazingly enabling acquisitions,
majority in our onboarded virtually. the added the they are our Throughout which Over the and ultimately all source Our of more of we team were is XX of foundation XXX employees, of vast success. year, Company, working organization, were the than total to I'm so hires drawn these who to mission be brilliant, bringing the XXx. of and hard year-end. employees to at our passionate at continue individuals of commercial our our XXX commercial proud
our discoveries community. Last we're and progress. to by customers' this pandemic intensely the by great with Many understand acute customers develop work, their always, responded of to and disease motivated by presented COVID the fighting it. year, of unexpected to our scientific determination an their As challenge ways and
few major highlight I'd just As papers last the to in like weeks. published two an example,
In producing patients patients antibodies with COVID immune virus. functioning in systems fight the single the interfere immune The researchers expression San that immunotherapies in cell of pattern gene the severe patients patients. that of where mild points University mild defense. rogue They of from first and display that Nature system. California, coordinates sequencing severe contrast, proper discovered specific targets with reengage for with viral the severe to the used the potential This disease are published to compare came against and pattern disease, the in Francisco,
published age, a numbers and study in-depth therapeutic for China, across key samples of set on different The patients. the massive not were were XX study understanding able disease This clinical sex, performing changes from The COVID-XX analysis to including paper hundreds types second cell of for single-cell of This ran a features the appreciated. going a that from came nearly stage. strategies immune link consortium researchers made group hospitals. provides resource data and of from large rich previously COVID-XX severity institutes XXX effective for in of features, and multiple They forward. pathogenesis developing response revealed up to
remained in Chromium control. in drive work fourth navigating placements. instrument Customer drove pandemic, instruments engagement labs Demand Now, will reached this pull-through operating labs while biosafety a back state, strong usage have for pandemic steady this under we're adapted new within believe which We our the to environment. to and brought have quarter. customers is continue pre-COVID levels incremental still continues until to the
of study development Importantly, for our sites. using booked the to during improve process. first yield involving excited the the platform Chromium clinical from quarter, the drug multinational opportunity about collection we the XX We're biomarker samples
these We're growing fourth across existing cases. the areas XX during the papers have continued and accelerate translational about more Visium's talked Turning encouraged highly provide publications to research there in a especially critical number of in to Previously, our applications and preprints grow use believe validation and The Visium. markets, have platform and settings. of we adoption market will of pace in date. been oncology adoption and than exciting neuroscience. to by We quarter,
to we're cases use have be been our the continue by that also the drivers of adoption, Visium major new range While exploring. of these customers excited
targetable the There And those injury is of using of progression to for kidney antifibrotic normal disease, are in to liver understand spatial study congenital example, understand to heart chronic is to identify heart studies comparing biology better and pathways them Visium and from the being to atherosclerosis. For used therapies. temporal in customers kidney. kidney profiles understand obtain to conditions fibrosis of Visium a
the even very years, is days. over our it Now, with still early commercial success several past
XXXX, around our focused key four priorities. Looking to ahead are investments
establishing in First, scaling and build broader strategically genomics developing our business adoption; platform. of research; initiatives. as future infrastructure; building Chromium and ahead organization. to standard situ third, second, demand and driving We're spatial finally, our the for operational the drive our out Starting organizational with Visium to
least with Company to product earlier, global the our global operations, we throughout new to at As year also close plan R&D I and investments mentioned across ended commercial G&A. to infrastructure, expansion hire XXXX the in IT more making We're XXX and we support launches. XXX and employees,
grow our the of every support bring employee our Company talent our base rapid with capabilities closer pace product to approximately of a we We're acquired top investments, also over to have year. course these organization, the our As part the by R&D increase across plans land to of sophisticated part our to to XX% nearby development. hiring of manufacturing
done part preserving a of drives we continue These our and be on to been we been mission-driven As scale, that culture focused achieve never things will before. core nurturing critical and success. to are have that a have long-term values us
platform the in more has quickly remain and a revolution. the adoption opportunity. early impressive, its small its our is while Turning in We very cell cycle fraction of And of in single instruments. to it XXXX, to Since X,XXX scaled still very Chromium. than total launch impact a
already are molecular biology, across interest biology, of is they're away the across viewed is And products we're market of biology. clear starting whether life from tools from conventionally are biology. just many customers, it it's conventional new the standard all beginning. Our the this to continuing categories, distinct sciences the doing And as of sweep this cell protein seeing what that
that single of standard thousands expect biological for of cell of world. become We experiments around labs will tens many approaches the the across types
investing for Chromium early thousands content of the We're expanding to answering on to and for tens biologists keep half experiments experiments of and reduce focused from kit, and utility cell with of studies a broad biological increasing much barriers genomics to efficient RNA keep the enable We're In fixed use wide of to costs multiplexing reducing and allowing high kit launching specific CellPlex our cost point the to we genomics a market is live and total new range goal sailing. North single-cell to adoption new also questions. in along those fixation proof-of-concept computation. at configurations driving leaders million remove coming be allow routine collection, users Our Cloud to experiment the handling enable large to data quarter as this across a will established a Chromium that in year, to XX%; an experiments, launch X cases. is profiling kit that curve unlocking XXXX, enable high-throughput finally, And of large for as first quarter that the will Chromium product with customers X, more The accelerating capabilities following the users. the XXx start-up of first adoption to optimized the will now a enable And streamlined before sample American launching cost of for tissue by back access low-throughput the for cells. new cohorts. instrument will technologies
is Visium platform elucidating quarters cycle been product compared resolution its Chromium. five spatial on adoption than is for powerful This has on Moving life market This highest the in and biology gained to Visium. and already market. the to remains incredibly earlier platform genomics but for broad has overall spatial less the adoption. in
the sensitivity it expanding a comprising reagents product and focused samples true discovery which technology the delivering across is in customers. entire product as part standard research that the We're What's Visium for analyzing expectations, year. very the performance shipping even biggest condition our see and is in translational samples, transcriptome is This with with full launching market quarter especially FFPE customers, future to is their complete tissue. Visium. to patient for remarkable standard second in core fact, fresh FFPE launches, response stored the its compatibility exceeds that software. enable genomics on with predominant We capabilities are and this what and way on FFPE, for is of it's A the starting establishing aggressive we It about This solution, request with begin now the We're research first pathology excited internal ready-to-use workflows. is of in all this samples. to with single the collected most necessary are expect par of the standard the spatial very of to our exciting tissues we demand.
Assist. this is the customers the instrument that first already to to help like mounted handling our sample received analyze on have FFPE new capabilities, to logistics. would To samples and from Visium half Most addition key answer importantly, we XXXX, Site our to of need, launch non-Visium a request have In conventional customers archived called a we in been slides. plan
on Visium the launch address customers and in of Visium large different as for breadth translational long-term The in a biology for This most foundation sub-cellular analytical a To directly represent whole. publications molecules best And a our simplify ability promise most Visium the customers we their the Visium help a with investments opportunity and that XXXX workflow situ half driving and techniques at be translational the spatial initial variety that's times and significant We on market native to from numbers microarray resolution We expect times current significantly run adoption resolution. higher come It XXX technology. together first vector. early new for keep platform will where the than us other cell HD make the current tissue growth fundamental the capabilities, samples FFPE we're in really and state at X,XXX than translational resolution. making, will in of our advances big Site will of situ believe molecules all in over the expect based before from will pre-Visium original help deliver are is have to this, the of Visium. will we of the the and expand launching of the the finally, single Visium expect network the with our single scientific The of Assist higher that platform, the and of underlying measurement. we to as pace the for technology. HD highly clinical will Visium then year we enthusiasm many discovery of story. of could Chromium, number Visium expand our protein another measure that this establish in of assays. And and the multiplexed customers addition from removed We're ahead platform Visium research. platform tissue is very beginning the our finally, or is added with
In to be more instrument work scale done an and analysis. for expect which multiplex foundation that approaches, basic run, of one long and situ these laid but at greater natural the the integrated to whether every provide gets adopted approaches, for will using format We build expect Chromium of levels vastly Visium, in can IHC insights tissue-based be These science as applications. commonly medical research information and as ideal or of we least the for clinical translational tissue in these FISH-based system, used an clinic. with viewed content. the analyzed for be will about analogous pathology, And just to applications many capabilities for to three in
people Moving of science beyond tools approximately market. looking research This discuss our currently $XX as previously market life represents research let opportunity where within near-term those outlined billion billion me do view areas the our $XX the global throughput high the XXXX, on opportunity. to more We are tools than market research.
more As time. available to tools over the of to market total the will large-scale approaches, more life research research science high-resolution, moves us become
In addition, and be analysis spatial there will powerful based clinical of on cell tissues. single applications eventually many
of in We of clinic. the diversity size billion. thought, If them is pervasive complexity modest the biology over the all cell $XX system. positioned revelation previously platform this many greatest around around harbors underlies opportunity well past cells massive had networks. years estimate pricing, types will than the a cellular additional It potential situ be each of to expect of interacting that of we and other every we samples our assumptions the we to just several out bring every in and turns is that in numbers the gene make those Perhaps an with about greater of much applications tissue expression complex biological interplay
investing looking our feature been their turn not us grow for With this on will at growth. year. with we that, our of work we ahead to and I the I to Overall, that be vast of enable Justin past context in Their in now more at now, stories scale team strong that the century have future, write to over their platforms our the the more for And foundation three financials. biology. than be and long-term high samples our XXXX core need clear call precisely And tissue more revenues together for will to XX% in execution expect resolution. details this of hard expertise could as analyzed customers have proud is will large laid cell XXXX. biological a it they single forward, over Going for majority talent, of
